AHA: Addressing ‘undiagnosed’ NAFLD could mitigate CVD risk
Nonalcoholic fatty liver disease remains widely undiagnosed, yet early identification and treatment could mitigate long-term risk for CVD, according to a new American Heart Association scientific statement.Nonalcoholic fatty liver disease (NAFLD) is believed to affect at least 25% of adults worldwide, according to the AHA. Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs; hepatic complications include nonalcoholic steatohepatitis (NASH), hepatic cirrhosis and hepatocellular carcinoma. NAFLDRead More
